Biologics in the treatment of psoriasis and emerging new therapies in the pipeline

References

• Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23–26.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197–1204.
   Web of Science ®Google Scholar
• Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442–447.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Turka LA, Mitra RS, Nestle FO. Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol. 1995;105(Suppl 1):25S–29S.
   Web of Science ®Google Scholar
• Braun-Falco O, Schmoeckel C. The dermal inflammatory reaction in initial psoriatic lesions. Arch Dermatol Res. 1977;258(1):9–16.
   Web of Science ®Google Scholar
• Baker BS, Swain AF, Valdimarsson H, Fry L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol. 1984;110(1): 37–44.
   Web of Science ®Google Scholar
• Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256(22):3110–3116.
   Web of Science ®Google Scholar
• Fierlbeck G, Rassner G, Müller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol. 1990;126(3):351–355.
   PubMedGoogle Scholar
• Nograles KE, Krueger JG. Anti-cytokine therapies for psoriasis. Exp Cell Res. 2011;317(9):1293–1300.
   PubMed Web of Science ®Google Scholar
• Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol. 2005;152(6):1098–1107.
   PubMed Web of Science ®Google Scholar
• Valdimarsson H, Baker BS, Jönsdöttir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today. 1995;16(3):145–149.
   Google Scholar
• Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664–1675.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Cornelissen F, van Hamburg JP, Lubberts E. The IL-12/IL-23 axis and its role in Th17 cell development, pathology and plasticity in arthritis. Curr Opin Investig Drugs. 2009;10(5):452–462.
   Google Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79–88.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN -gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008;181(7):4733–4741.
   PubMed Web of Science ®Google Scholar
• Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severity. Clin Exp Dermatol. 1994;19(5):383–387.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687.
   PubMed Web of Science ®Google Scholar
• Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets. 2011;15(2):119–126.
   PubMed Web of Science ®Google Scholar
• Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178(4):2229–2240.
   PubMed Web of Science ®Google Scholar
• Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695–3702.
   PubMed Web of Science ®Google Scholar
• He M, Liang P. IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol. 2010;184(4):1793–1798.
   Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-a levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163(6):1282–1290.
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–1383.
   PubMed Web of Science ®Google Scholar
• Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci. 2010;58(3):225–227.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–943.
   PubMed Web of Science ®Google Scholar
• Naldi L, Svensson A, Diepgen T, et al; for European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. J Invest Dermatol. 2003;120(5):738–741.
   Google Scholar
• Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004;51(4):563–569.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Pèrez A, Chen TC, Turner A, et al. Efficacy and safety of topical calcitriol (1,25 dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol. 1996;134(2):238–246.
   Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;2: CD005028.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–837.
   PubMed Web of Science ®Google Scholar
• Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB; for National Psoriasis Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010;62(5):838–853.
   PubMed Web of Science ®Google Scholar
• Amevive [package insert]. Cambridge, MA: Biogen Inc; December 2011.
   Google Scholar
• Enbrel [package insert]. Thousand Oaks, CA: Amgen; December 2011.
   Google Scholar
• Remicade [package insert]. Horsham, PA: Janssen Biotech Inc; October 2011.
   Google Scholar
• Humira [package insert]. North Chicago, IL: Abbott Laboratories; December 2011.
   Google Scholar
• Stelara [package insert]. Horsham, PA: Janssen Biotech Inc; August 2011.
   Google Scholar
• Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46–54.
   Google Scholar
• Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm. 2010;16(6):402–416.
   PubMed Web of Science ®Google Scholar
• Raptiva [package insert] South San Francisco, CA: Genentech Inc; 2006.
   Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.
   PubMed Web of Science ®Google Scholar
• Chamian F, Lin SL, Lee E, et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007;5:27.
   PubMed Web of Science ®Google Scholar
• Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994;152(6):2753–2767.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; for Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139(6):719–727.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; for Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47(6):821–833.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2(6):624–628.
   PubMedGoogle Scholar
• Roberts JL, Ortonne JP, Tan JK, Jaracz E, Frankel E; for Alefacept Clinical Study Group. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. J Am Acad Dermatol. 2010;62(6):968–978.
   Web of Science ®Google Scholar
• Pugashetti R, Koo J. Efalizumab discontinuation: a practical strategy. J Dermatolog Treat. 2009;20(3):132–136.
   Web of Science ®Google Scholar
• Wexler D, Searles G, Landells I, et al. Update on alefacept safety. J Cutan Med Surg. 2009;13 Suppl 3:S139–S147.
   Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al; for Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al; for Etanercept Psoriasis Study Group. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised Phase III trial. Lancet. 2006;367(9504):29–35.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Griffiths C, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp Rev Dermatol. 2008;3:657–665.
   Google Scholar
• Daudén E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374–1382.
   PubMed Web of Science ®Google Scholar
• Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66(2):e33–e45.
   PubMedGoogle Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7(3):251–259.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al; for EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31, e1-e15.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis withbiologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Rozin AP. Infliximab efficiency and failure. Ann Rheum Dis. 2004;63(6):751–752.
   Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711–715.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138(5):686–688.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–1563.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled Phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–251.
   PubMed Web of Science ®Google Scholar
• Asahina A, Nakagawa H, Etoh T, Ohtsuki M; for Adalimumab M04–688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al; for CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
   PubMed Web of Science ®Google Scholar
• Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol. 2009;10(1):43–50.
   Web of Science ®Google Scholar
• Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127–132.
   PubMedGoogle Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48(11):3013–3022.
   PubMed Web of Science ®Google Scholar
• Kamili QA, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol. 2010;9(1):57–60.
   Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48(2):319–324.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol. 2009;21(4):397–403.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA Drug Safety Communication: Drug labels for the tumor necrosis factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. September 7, 2011. Available at: http://www.fda. gov/Drugs/DrugSafety/ucm270849.htm. Accessed April 9, 2012.
   Google Scholar
• Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45(6):953–956.
   Web of Science ®Google Scholar
• Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNF alpha blockade. J Am Acad Dermatol. 2004;51(4):660–662.
   Web of Science ®Google Scholar
• Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886–2895.
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladström A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64(5):699–703.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–2201.
   PubMed Web of Science ®Google Scholar
• Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol. 2010;162(6):1349–1358.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Cooper KD, McCormick TS, et al. A Phase 1, doubleblind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23(5):1081–1092.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al; for CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–592.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al; for PHOENIX 1study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al; for PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010;162(1):137–146.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, et al; for ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66:742–751.
   PubMed Web of Science ®Google Scholar
• Reich K, Leonardi C, Griffiths CEM, et al. Update on the cumulative safety experience of ustekinumab: results from the ustekinumab psoriasis clinical development program with up to 4 years of follow-up. Presented at the 22nd World Congress of Dermatology, May 24–29, 2011, Seoul, Korea.
   Google Scholar
• Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from Phase II and III clinical studies. Br J Dermatol 2011;164(4):862–872.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–1006.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–871.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha – California, 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53(30):683–686.
   Google Scholar
• Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58(1):94–105.
   Web of Science ®Google Scholar
• Levine D, Strober BE. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Semin Cutan Med Surg. 2010;29(1):28–34.
   Web of Science ®Google Scholar
• Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J Clin Aesthet Dermatol. 2010;3(8):20–26.
   PubMedGoogle Scholar
• ClinicalTrials.gov. Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE).Available at: http://clinicaltrials.gov/ct2/show/ NCT01412944. Accessed April 18, 2012.
   Google Scholar
• ClinicalTrials.gov. Efficacy at 24 weeks and long term safety, tolerability and efficacy up to 2 years of secukinumab (AIN457) in patients with active psoriatic arthritis (PsA). Available at: http://clinicaltrials. gov/ct2/show/NCT01392326. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Efficacy at 24 weeks and safety, tolerability and long term efficacy up to 1 year of secukinumab (AIN457) in patients with active rheumatoid arthritis (RA) and an inadequate response to anti-tumor necrosis factor a (anti-TNFa) agents. Available at: http://clinicaltrials. gov/ct2/show/NCT01350804. Accessed November 21, 2011.
   Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
   PubMed Web of Science ®Google Scholar
• Papp K, Sigurgeirrson B, Abe M, et al. Secukinumab efficacy and safety preliminary results from a Phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis. Presented at the 20th Congress of the European Academy of Dermatology and Venereology, October 20–24, 2011, Lisbon, Portugal.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year (ERASURE). Available at: http://clinicaltrials.gov/ct2/show/ NCT01365455. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens (SCULPTURE). Available at: http://clinicaltrials.gov/ct2/show/NCT01406938. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Study to assess the long-term safety, tolerability, and efficacy of AMG 827 in subjects with psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT01101100. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy of AMG 827 in subjects with RA. Available at: http://clinicaltrials.gov/ct2/show/NCT01059448. Accessed November 21, 2011.
   Google Scholar
• Russell CB, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG 827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol. 2010; 130 Suppl 1:S46.
   Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, doubleblind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929–939.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A dose-ranging and efficacy study of LY2439821 (an anti-IL-17 antibody) in patients with moderate-to-severe psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT01107457. Accessed November 18, 2011.
   Google Scholar
• ClinicalTrials.gov. A Phase 3 study in participants with moderate to severe psoriasis (UNCOVER-1). Available at: http://clinicaltrials.gov/ ct2/show/NCT01474512. Accessed November 18, 2011.
   Google Scholar
• ClinicalTrials.gov. Study evaluating the safety and tolerability of ILV-094 in subjects with psoriasis. Available at: http://clinicaltrials. gov/ct2/show/NCT00563524. Accessed November 18, 2011.
   Google Scholar
• ClinicalTrials.gov. Study to evaluate the safety and efficacy of ILV-094 in subjects with rheumatoid arthritis. Available at: http://clinicaltrials.gov/ct2/show/NCT00883896. Accessed November 21, 2011.
   Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Monthly prescribing reference. Phase 2b study of apremilast for treatment of plaque-type psoriasis. December 16, 2009. Available at: http://www.empr.com/phase-2b-study-of-apremilast-for-treatment-of-plaque- type-psoriasis/article/159730. Accessed November 18, 2011.
   Google Scholar
• ClinicalTrials.gov. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 1). Available at: http://clinicaltrials.gov/ct2/show/ NCT01194219. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 2). Available at: http://clinicaltrials.gov/ct2/show/ NCT01232283. Accessed November 21, 2011.
   Google Scholar
• Bissonnette R, Papp K, Poulin Y, et al; for ISA247 Psoriasis Study Group. A randomized, multicenter, double-blind, placebo-controlled Phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol 2006;54(3):472–478.
   PubMed Web of Science ®Google Scholar
• Aspeslet L, Freitag D, Trepanier D, et al. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc. 2001;33(1–2):1048–1051.
   PubMed Web of Science ®Google Scholar
• Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled Phase III study. Lancet. 2008;371(9621):1337–1342.
   PubMed Web of Science ®Google Scholar
• Kunynetz R, Carey W, Thomas R, Toth D, Trafford T, Vender R. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian Phase III, randomized, multicenter, double-blind, placebocontrolled study. Eur J Dermatol 2011;21(1):89–94.
   PubMed Web of Science ®Google Scholar
• Voclosporin Psoriasis Clinical Trials. Phase 3 combined European/ Canadian (ESSENCE) trial. Available at: http://www.isotechnika.com/in_development/clinical_trials/voclosporin. Accessed November 18, 2011.
   Google Scholar
• Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum. 2009;60(10):3061–3071.
   PubMedGoogle Scholar
• David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012;26(3):361–367.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Trial of CF101 to treat patients with psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT01265667. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Trial of CF101 to treat patients with dry eye disease. Available at: http://clinicaltrials.gov/ct2/show/NCT01235234. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy of daily CF101 administered orally in subjects with elevated intraocular pressure. Available at: http://clinicaltrials.gov/ct2/show/NCT01033422. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. A study of the efficacy and safety of CF101 to patients with osteoarthritis of the knee. Available at: http://clinicaltrials. gov/ct2/show/NCT00837291. Accessed November 21, 2011.
   Google Scholar
• Wagner J, von Matt P, Faller B, et al. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem. 2011;54(17):6028–6039.
   PubMed Web of Science ®Google Scholar
• Matz M, Weber U, Mashreghi MF, et al. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant. 2010;25(7):2159–2167.
   Web of Science ®Google Scholar
• Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest. 2008;118(9):3151–3159.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A dose finding study of AEB071 assessing Psoriasis Area and Severity Index in patients with plaque psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT0885196. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis. Available at: http://clinicaltrials.gov/ct2/show/NCT00572585. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Efficacy, safety and tolerability of AEB071 versus cyclosporine in the novo renal transplant recipients. Available at: http://clinicaltrials.gov/ct2/show/NCT00504543. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy of AEB071 in metastatic uveal melanoma patients. Available at: http://clinicaltrials.gov/ct2/show/ NCT01430416. Accessed November 21, 2011.
   Google Scholar
• Norman P. BMS-582949: crystalline form of a p38alpha inhibitor? W02008079857. Expert Opin Ther Pat. 2009;19(8):1165–1168.
   PubMed Web of Science ®Google Scholar
• Medicherla S, Ma JY, Reddy M, et al. Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig. J Inflamm Res. 2010;3:9–16.
   Google Scholar
• ClinicalTrials.gov. A study of BMS-582949 in patients with moderate to severe plaque psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT00399906. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. PoC in rheumatoid arthritis with methotrexate. Available at: http://clinicaltrials.gov/ct2/show/NCT00605735. Accessed November 21, 2011.
   Google Scholar
• ClinicalTrials.gov. Efficacy study of p38 kinase inhibitor to treat patients with atherosclerosis. Available at: http://clinicaltrials.gov/ ct2/show/NCT00570752. Accessed November 21, 2011.
   Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243.
   PubMed Web of Science ®Google Scholar
• Businesswire. Oral tasocitinib demonstrates statistically significant response by 12 weeks in Phase 2 study of people with moderate to severe plaque psoriasis. October 7, 2010. Available at: http://www.businesswire.com/news/home/20101130006239/en/Oral-Tasocitinib-Demonstrates-Statistically-Significant-Response-12. Accessed November 18, 2011.
   Google Scholar
• ClinicalTrials.gov. A one-year study to evaluate the efficacy and safety of CP-690,550 for patients with moderate to severe chronic plaque psoriasis. Available at: http://clinicaltrials.gov/ct2/show/NCT01309737. Accessed December 6, 2011.
   Google Scholar
• Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009;183(3):2183–2192.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–1844.
   PubMed Web of Science ®Google Scholar
• Incyte Coorporation. Product pipeline. Available at http://www.incytedrugs.com/drugproductpipeline.html. Accessed December 6, 2011.
   Google Scholar
• ClinicalTrials.gov. A study of INCB018424 phosphate cream when applied to patients with plaque psoriasis. Available at: http://clinicaltrials. gov/ct2/show/NCT00820950. Accessed December 6, 2011.
   Google Scholar
• ClinicalTrials.gov. Study of INCB018424 sustained release formulation in myelofibrosis patients. Available at: http://clinicaltrials. gov/ct2/show/NCT01340651. Accessed December 6, 2011.
   Google Scholar
• ClinicalTrials.gov. Study of INCB018424 for acute leukemia. Available at: http://clinicaltrials.gov/ct2/show/NCT01251965. Accessed December 6, 2011.
   Google Scholar
• ClinicalTrials.gov. Study to determine the safety and efficacy of ruxolitinib (INCB018424) in patients with polycythemia vera or essential thrombocythemia. Available at: http://clinicaltrials.gov/ct2/show/NCT00726232. Accessed December 6, 2011.
   Google Scholar